New drug cocktail targets hard-to-treat stomach cancer before surgery
NCT ID NCT07569068
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether adding a targeted drug (LM-302) to standard immunotherapy and chemotherapy before surgery can improve outcomes for people with a specific type of stomach cancer that has a protein called claudin 18.2. About 88 adults with advanced but removable stomach cancer will be randomly assigned to one of two treatment combinations. The main goal is to see how many patients have no cancer left in their removed tissue.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tislelizumab, LM-302, S-1, and oxaliplatin
What this could lead to
If successful, this could offer a more effective pre-surgery treatment for a specific type of stomach cancer, potentially improving the chance of complete tumor removal.
What could go wrong
This is an early Phase 2 exploratory study with only 88 participants, so results may not apply broadly. The combination therapy may cause more side effects than standard treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC OR ESOPHAGOGASTRIC JUNCTION ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ruijin Hospital Shanghai Jiao Tong University School of Medicine
RECRUITINGShanghai, Huangpu District, 200025, China